











































Discontinuation of Initial Antiretroviral Therapy in Clinical
Practice: Moving Toward Individualized Therapy
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Background: Study aim was to estimate the rate and identify
predictors of discontinuation of first combination antiretroviral
therapy (cART) in recent years.
Methods: Patients who initiated first cART between January 2008
and October 2014 were included. Discontinuation was defined as
stop of at least 1 drug of the regimen, regardless of the reason. All
causes of discontinuation were evaluated and 3 main endpoints were
considered: toxicity, intolerance, and simplification. Predictors of
discontinuation were examined separately for all 3 endpoints.
Kaplan–Meier analysis was used for the outcome discontinuation
of $1 drug regardless of the reason. Cox regression analysis was
used to identify factors associated with treatment discontinuation
because of the 3 reasons considered.
Results: A total of 4052 patients were included. Main reason for
stopping at least 1 drug were simplification (29%), intolerance (21%),
toxicity (19%), other causes (18%), failure (8%), planned discontin-
uation (4%), and nonadherence (2%). In a multivariable Cox model,
predictors of discontinuation for simplification were heterosexual
transmission (P = 0.007), being immigrant (P = 0.017), higher nadir
lymphocyte T CD4+ cell (P = 0.011), and higher lymphocyte T CD8+
cell count (P = 0.025); for discontinuation due to intolerance: the use
of statins (P = 0.029), higher blood glucose levels (P = 0.050). About
toxicity: higher blood glucose levels (P = 0.010) and the use of
zidovudine/lamivudine as backbone (P = 0.044).
Conclusions: In the late cART era, the main reason for stopping
the initial regimen is simplification. This scenario reflects the
changes in recommendations aimed to enhance adherence and
quality of life, and minimize drug toxicity.
Key Words: antiretroviral therapy, HIV-1, discontinuation, resump-
tion treatment, single-tablet regimen, first-line therapy
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INTRODUCTION
The expanded use of combination antiretroviral therapy
(cART) since 1996 has resulted in a marked and sustained
decrease in AIDS-related morbidity and mortality,1–3 with
a range of benefits to HIV-infected patients, such as increased
survival, improved immune status, and decreased of oppor-
tunistic infections.4–6 Current regimen options are more
effective, better tolerated, less toxic, than regimens used in
the early years of the cART era7; therefore, optimization of
initial antiretroviral therapy in terms of both virological
efficacy and tolerability is essential because long-term
toxicity and persistency are fundamental features in the
choice of first-line cART. Rates and reasons for discontinu-
ation or modifications of the first-line cART regimens have
been investigated in a number of recent studies8–17 in which it
has been underlined how discontinuation of initial therapy has
decreased over time, but is still quite high even for the latest
drug combinations.16 Data updated from the Italian Cohort
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of Antiretroviral-Naive Patients (ICONA) on 2008 high-
lighted a 1-year probability of first cART stopping of
36.1%; moreover, it has been noticed that the incidence of
discontinuation because of intolerance/toxicity has declined
over time, whereas simplification strategies have become
more frequent in recent years.11 The latest advances in
refinement of cART strategies, regarding both new drugs
and fixed dose formulations, have led to reconsider and
change current guidelines for first antiretroviral regimens in
naive patients,18 as has already happened for multiple other
drugs in the past years.19
Furthermore, evaluations of the prevalence and predic-
tors of initial cART discontinuation have demonstrated that
certain patients are more likely to discontinue treatment.20–22
For this reason, identifying groups at increased risk of cART
discontinuation could support clinicians in the choice and
optimization of first-line therapy for the individual patient.
The aims of this analysis were (1) to estimate the
frequency and causes of discontinuation of treatment regi-
mens initiated in very recent years in HIV-infected patients




ICONA Foundation Study (ICONA) is a multicenter
prospective observational study of HIV-1–infected patients,
which was set up in 1997. Eligible patients were those starting
cART when they were naive to antiretrovirals, regardless of
the reason for which they had never been treated and the stage
of the disease. All patients signed consent forms to participate
to the ICONA, in accordance with the ethical standards of the
committee on human experimentation and the Helsinki
Declaration (1983 revision). Demographic, clinical and
laboratory data, and information on therapy are collected
for all participants and recorded online www.icona.org.
Patients who had initiated their initial cART regimen
after January 1, 2008 and had at least 1 month of clinical
follow-up were included in this analysis; follow-up lasts up
to the end of October 2014. Discontinuation of the first
regimen was defined as stopping and/or switching of at least
1 drug contained in the regimen; we had ignored all changes
in formulations that did not imply a modification in the drug
used [eg, changing from tenofovir/emtricitabine (TDF/FTC)
plus efavirenz (EFV) to a single-tablet regimen (STR)
containing TDF/FTC/EFV]. All causes of discontinuation
were coded in the ICONA database, including simplification
(defined either as the reduction of drugs included in the
regimen or the decrease in daily doses or pills); intolerance
defined as patient’s related lack of tolerance (eg, unwilling-
ness or refusal to tolerate the prescribed drug in the absence
of any clinical and laboratory signs of drug harmfulness);
toxicity defined as a stop likely to be caused by adverse
effects related to exposure to that drug. This includes
drug-related side effects and adverse reactions, defined as
the response to a drug, which is noxious and unintended
and which occurs at normally used doses; failure (either
virological or clinical); nonadherence; planned discontinu-
ation (including structured treatment discontinuation, end of
pregnancy, and medical decision); other causes (including
patients decision, pregnancy, enrollment, or ending of
a clinical trial and drug–drug interaction), as reported by
the treating physician. Three main discontinuation endpoints
have been considered: (1) because of toxicity, (2) intoler-
ance, and (3) simplification. These have been decided a priori
as likely to be the 3 main reasons for stopping drugs in the
modern era of cART, as previously shown.11 Potential
predictors of the risk of stopping, which have been
examined separately for all 3 endpoints, included: sex,
mode of HIV transmission, nationality (an immigrant patient
was considered a patient born outside Italy), AIDS diagno-
sis, cardiovascular disease diagnosis, hepatitis B and C
diagnosis, calendar year of baseline, age, lymphocyte T
CD4+ and CD8+ cell count, HIV-RNA plasma level,
diabetes, total cholesterol, and high-density lipoproteins
cholesterol (categorical variable, above and below 40 mg/
dL for men and 50 mg/dL for women), use of statins, use of
blood pressure lowering drugs, time from HIV diagnosis to
date of starting cART, estimated glomerular filtration rate,
blood glucose, third drug and backbone combined in the
regimen, mental health disorders.
Statistical Analysis
Standard survival analysis was used to estimate the
time to treatment discontinuation (endpoints defined as
above). Patients’ follow-up accrued from the date of starting
their first cART regimen from ART-naive up to the date of
discontinuation or last clinical visit. Kaplan–Meier (KM)
curves were drawn using a marginal model approach such as
follow-up of patients who discontinued for a reason different
from that of interest was truncated at the date of last clinical
follow-up (administrative censoring). Overall cumulative
risk of stopping was estimated using the KM method and all
curves stratified by reason fore stopping were plotted on the
same graph. Cox regression analysis was used to identify
factors associated with the risk of treatment discontinuation
because of the 3 reasons described. We used a cause-specific
hazard approach as our main analysis and the Fine–Gray
approach as an alternative analysis with the objective of
prediction (see Table S1, S2, S3, Supplemental Digital
Content, http://links.lww.com/QAI/A754). All variables
considered in the univariable model have been also included
in the multivariable model.
RESULTS
We included in the study 4052 patients, satisfying the
entry criteria. Men were 3197 (78.9%), mean age was 39
years (range: 32–47 years), 796 patients (19.6%) were 18–30
year old, 2562 (63.2%) were 31–50 years old and 694
(17.1%) were more than 50 old. In Table 1, demographic
characteristics of patients included in the study are illustrated.
The most frequently prescribed regimens and their prescrip-
tive distribution over time are showed in Table 2. Globally,
protease inhibitor (PI)–containing regimens accounted for the
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TABLE 1. ART Discontinuation and Reasons in Late cART Era
Characteristics
Discontinuation
Yes (N = 1389) No (N = 2663) P* Total (N = 4052)
Gender, n (%) 0.043
Female 318 (22.9) 537 (20.2) 855 (21.1%)
Mode of transmission, n (%) 0.166
Intravenous drug use 103 (7.4) 229 (8.6) 332 (8.2)
Homosexual contacts 569 (41.1) 1068 (40.3) 1637 (40.6)
Heterosexual contacts 617 (44.4) 1133 (42.5) 1750 (43.2)
Other/unknown 95 (6.9) 222 (8.4) 317 (7.9)
Nationality, n (%) 0.169
Being immigrant 253 (18.2) 598 (22.5) 851 (21.0)
AIDS diagnosis, n (%) 0.062
Yes 168 (12.1) 271 (10.2) 439 (10.8)
Calendar year of baseline ,0.001
Median (IQR) 2011 (2009, 2012) 2012 (2011, 2013) 2012 (2010, 2013)
Age, years ,0.001
Median (IQR) 40 (33, 48) 39 (32, 47) 39 (32, 47)
CD4 count, cells/mmc 0.007
Median (IQR) 297 (159, 400) 313 (185, 422) 308 (176, 413)
CD4 count nadir, cells/mmc 0.029
Median (IQR) 284 (155, 382) 300 (173, 394) 294 (166, 391)
CD8 count, cells/mmc 0.683
Median (IQR) 655 (473, 820) 660 (474, 832) 659 (473, 826)
Viral load, log10 copies/mL 0.019
Median (IQR) 4.77 (4.13, 5.27) 4.68 (4.02, 5.21) 4.71 (4.05, 5.23)
Total cholesterol, mg/dL 0.266
Median (IQR) 160 (136, 184) 161 (137, 187) 161 (136, 186)
HDL cholesterol, mg/dL 0.592
Median (IQR) 38 (31, 47) 38 (31, 47) 38 (31, 47)
Use of statins, n (%) 0.054
Yes 26 (1.9) 30 (1.1) 56 (1.4)
Blood glucose, mg/dL 0.838
Median (IQR) 86 (79, 94) 86 (79, 94) 86 (79, 94)
Antivirals started, n (%)
Zidovudine 96 (6.9) 52 (2.0) 148 (3.7)
Lamivudine 199 (14.3) 360 (13.5) 559 (13.8)
Abacavir 90 (6.5) 285 (10.7) 375 (9.3)
Tenofovir 1192 (85.8) 2310 (86.7) 3502 (86.4)
Emtricitabine 1181 (85.0) 2295 (86.2) 3476 (85.8)
Efavirenz 503 (36.2) 704 (26.4) 1207 (29.8)
Nevirapine 23 (1.7) 56 (2.1) 79 (1.9)
Rilpivirine 8 (0.6) 304 (11.4) 312 (7.7)
Liponavir/r 279 (20.1) 200 (7.5) 479 (11.8)
Atazanavir/r 308 (22.2) 611 (22.9) 919 (22.7)
Darunavir/r 206 (14.8) 630 (23.7) 836 (20.6)
Raltegravir 48 (3.5) 115 (4.3) 163 (4.0)
Age (yrs), n (%) 0.002
18–30 246 (17.7) 550 (20.7) 796 (19.6)
31–50 870 (62.6) 1692 (63.5) 2562 (63.2)
50+ 273 (19.7) 421 (15.8) 694 (17.1)
*Chi-square or Kruskal–Wallis test as appropriate.
HDL, high-density lipoprotein; IQR, interquartile range; r, ritonavir.
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55.6% of the patients (n = 2252), non-nucleoside reverse
transcriptase inhibitors–containing regimens were the first-
line choice in 39.5% of the patients (n = 1601); in 199
patients (4.9%), integrase inhibitors and/or CCR5 inhibitors
were the third drugs of combinations (raltegravir was used as
part of 126 regimens). Looking at the NRTI backbone, in
3472 patients (85.7%), TDF/FTC was used; in 375 (9.2%)
and 145 (3.6%), the backbone was represented by abacavir/
lamivudine and zidovudine/lamivudine respectively.
Over a median follow-up of 12 months, 1389 patients
stopped their cART with an overall discontinuation rate
of 34.3%.
The likelihood of discontinuation by KM was 26% by 1
year [95% confidence interval (CI): 23.8 to 28.2], 39.7% by 2
years (95% CI: 37.0 to 42.4), and 48.5% by 3 years (95% CI:
45.4 to 51.6), as showed in Figure 1. Main reason for
stopping at least 1 drug in regimen was simplification
(29.1%), followed by intolerance (21.1%), toxicity (18.6%),
other causes (17.8%), failure (8.2%), planned interruption
(3.5%), and poor adherence (1.7%). Reasons for discontinu-
ation by year since starting cART are illustrated in Figure 2.
Three hundred seven patients (76%) simplified their regimens
to STR as second-line cART [268 patients in TDF/FTC/EFV
and 39 patients in TDF/FTC/rilpivirine (RPV)].
In a multivariable Cox model, independent predictors
of discontinuation for the main reasons (simplification,
intolerance, and toxicity) were analyzed (Table 3). Indepen-
dent predictors associated with higher likelihood of simpli-
fication were heterosexual intercourse as risk factor for HIV
transmission [hazard ratio (HR) 5.13; CI: 95% 1.57 to 16.74;
P = 0.007] and a higher nadir lymphocyte T CD4+ cell (HR
1.72; CI: 95% 1.13 to 2.61; P = 0.011), whereas being
immigrant (HR 0.39; CI: 95% 0.18 to 0.85; P = 0.017),
higher pretreatment lymphocyte T CD8+ cell counts (HR
0.89; CI: 95% 0.81 to 0.99; P = 0.025) were associated with
lower likelihood.
For discontinuation due to intolerance, an association
was found using statins (HR 2.99; CI: 95% 1.11 to 7.69; P =
0.029) and higher blood glucose levels (HR 2.11 CI: 95%
1.00 to 4.47). Independent predictors of discontinuation due
to toxicity were higher blood glucose levels (HR 3.12; CI:
95% 1.31 to 7.41; P = 0.010) and the use of zidovudine/
lamivudine as backbone (HR 3.72 CI: 95%1.04 to 13.34;
P = 0.044).
Among available data (n = 3638) about virological
status at 2 years after starting cART, 3597 patients (98.9%)
achieved viral suppression with HIV-RNA, 50 copies per
milliliter (see Figure S1, Supplemental Digital Content,
http://links.lww.com/QAI/A754).
DISCUSSION
In this analysis from the ICONA cohort, we offer new
data for estimating the proportion of HIV-infected naive
patients who discontinue their first-line cART and for
identifying characteristics associated with treatment discon-
tinuation in clinical practice. By our data, in the late of
antiretroviral therapy era, the main reason for stopping the
first-line treatment is simplification. These data suggest that
there is an ongoing prescriptive trend, which leads to
prioritize the regimen choice by simplifying the cART to
enhance patient adherence, improve quality of life, minimize
drug-related toxicity, and eventually provide a cost contain-
ment, because of an increase in the number of available drugs
and regimen combination options and according to the
changes in national and international recommendations.18,23
TABLE 2. Most Frequent Regimens and Their Prescriptive
Distribution Over Time
Regimens Years
Frequency 2008–2010 2011–2012 2013–2014 Total
Abacavir/lamivudine
+atazanavir/ritonavir
23 52 37 112





9 52 51 112
0.22 1.28 1.26 2.76
8.04 46.43 45.54
0.76 3.15 4.17
Other 172 196 106 474





220 385 177 782





94 341 256 691





230 69 44 343





27 41 58 126





402 512 203 1117





0 3 292 295
0.00 0.07 7.21 7.28
0.00 1.02 98.98
0.00 0.18 23.86
Total 1177 1651 1224 4052
29.05 40.75 30.21 100.00
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In a previously reported analysis of the ICONA cohort
conducted from January 2007 to June 200811 in the first year
after cART initiation, the overall risk of discontinuation of
initial therapy was 36% with 5.2% because of simplification.
In this analysis, the simplification reaches 29%: the use of
new drug combinations aimed to simplify dosing frequency
and reduce pill burden as STR. In this cohort, it has been
highlighted a great rate of simplification to STR (76.%). In
fact, it has been suggested that the performance of patients
who switched to an STR compared to patients remaining on
a more complex regimen is better, both in terms of virological
response and persistence.24–26 Furthermore, this high rate of
simplifications may also reflect the increase frequency of
pro-active switches in virologically suppressed patients
finalized to prevent long-term toxicity in a population that
is expected to become older and have age-related comorbid-
ities similarly to non-HIV–infected people.27 Moreover, the
Italian economic crisis, with the contraction of the govern-
ment budget, favors cheaper drugs and/or alternative treat-
ment regimens, might have played a role in influencing the
decision of clinicians on behalf of switches strategies.28
Indeed, in our country, STRs (TDF/FTC/EFV and TDF/
FTC/RPV) are cheaper than PI/r-based regimes and TDF/
FTC/EVG/cobicistat price is comparable to that of PI/r-based
regimens. We were not referring to the comparison of the
price of STR with that of its non-STR equivalent.
In our cohort rate of treatment, discontinuation due to
poor adherence was only 1.7% versus 24% in the previous
ICONA analysis; these data reflect the improvements of drug
formulation and regimen convenience, and the trend of
clinicians in favor of individualization of cART. Moreover,
the recent introduction of the fixed-dose, single-tablet formu-
lation of TDF/FTC/RPV for the treatment of HIV-infected
adults with a more favorable tolerability profile than TDF/FTC/
EFV have contributed in improving patient adherence.29–33
It is important to underline that at the time of this
analysis TDF/FTC/elvitegravir/cobicistat and dolutegravir were
not available in Italy, whereas the use of TDF/FTC/RPV was
not available for the switch on the whole Italian peninsula.
These data may support the auspice that in a next future,
discontinuation rate due to low adherence and intolerance will
decrease over time thanks to the second wave of STR (TDF/
FTC/elvitegravir/cobicistat, abacavir/lamivudine/dolutegravir)
and the new formulations containing protease inhibitors
(darunavir and atazanavir) plus cobicistat. Furthermore,
because of evolving guidelines recommendations, more
FIGURE 1. Overall Kaplan–Meier es-
timates of the risk of stopping.
FIGURE 2. Kaplan–Meier estimates according to reason for
stopping. STI, structured treatment interruptions.
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Relative Hazards of Discontinuation
Due to Intolerance









(95% CI) P Global P
Adjusted Relative
Hazards (95% CI) P Global P
Gender
Female versus male 1.15 (0.72 to 1.19) 0.640 1.36 (0.70 to 2.65) 0.366 1.10 (0.49 to 2.51) 0.813
Mode of HIV
transmission
Injection drug user 1.00 0.009 1.00 0.789 1.00 0.790
Homosexual contacts 3.79 (1.16 to
12.34)
0.027 0.94 (0.30 to 2.89) 0.910 0.60 (0.21 to 1.75) 0.352
Heterosexual contacts 5.13 (1.57 to
16.74)
0.007 1.14 (0.39 to 3.32) 0.809 0.37 (0.14 to 1.01) 0.053
Other/unknown 5.94 (1.47 to
24.08)




0.39 (0.18 to 0.85) 0.017 1.05 (0.51 to 2.16) 0.897 0.98 (0.40 to 2.38) 0.958
AIDS diagnosis
Yes versus no 1.76 (0.80 to 3.84) 0.159 0.27 (0.06 to 1.26) 0.097 1.37 (0.51 to 3.63) 0.531
Cardiovascular disease
Yes versus no 5.81 (0.67 to
50.76)
0.112 1.83 (0.19 to 18.02) 0.604
Hepatitis coinfection,*
n (%)
No 1.00 0.962 1.00 0.470 1.00
Yes 1.57 (0.74 to 3.35) 0.244 1.00 (0.37 to 2.66) 0.997 1.14 (0.43 to 3.02) 0.787
Not tested 0.78 (0.39 to 1.58) 0.490 1.68 (0.85 to 3.33) 0.134 1.21 (0.53 to 2.75) 0.655
Calendar year of baseline
Per more recent year 0.90 (0.77 to 1.05) 0.186 0.98 (0.81 to 1.19) 0.856 1.27 (1.00 to 1.62) 0.054
Age
















0.94 (0.77 to 1.16) 0.587 1.25 (0.96 to 1.63) 0.102 0.82 (0.62 to 1.08) 0.161
Diabetes, n (%)
Yes versus no 0.977 0.59 (0.05 to 7.10) 0.674 1.46 (0.21 to 10.45) 0.704
Total cholesterol
Per 100 mg/dL higher 1.22 (0.68 to 2.20) 0.504 0.56 (0.28 to 1.14) 0.199 0.99 (0.48 to 2.05) 0.976
HDL cholesterol
Altered versus normal 1.08 (0.70 to 1.66) 0.723 1.41 (0.83 to 2.40) 0.029 0.52 (0.27 to 1.03) 0.060
Use of statins
Yes versus no 1.30 (0.42 to 4.06) 0.651 1.41 (0.83 to 2.40) 0.199 0.94 (0.26 to 3.45) 0.926
Use of blood pressure
lowering drugs (%)
Yes versus no 0.69 (0.08 to 5.92) 0.731 1.36 (0.25 to 7.39) 0.029 2.12 (0.38 to 11.75) 0.391
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patients will start their first cART regimen directly with STR or
with integrase inhibitor including regimens and it could be
foreseen that the rate of switches due to simplification will
dramatically decrease.
A reduction of virological failure rate has been
observed in our cohort (8.2% versus 10.6% of previous
analysis): this could be due to the correct use of genotypic
resistance test at baseline in clinical practice and also to more
potent, more tolerated regimens.
Looking at simplification issues, in this analysis, we
found that being immigrants was correlated with a lower rate
of simplification. Notably, immigrant patients represent
a more vulnerable population: it has been already demon-
strated that immigrants are more likely to have a delayed in
access to HIV care and with concurrent advanced AIDS.34,35
Furthermore in HIV-infected immigrants, the rate of retention
to care is lower36 and the rate of adherence to cART.37 For
these reasons, Italian physicians might have used different
patterns of prescription for this population (eg, using
regimens with high barrier to resistance) and subsequently
immigrants have reduced possibility to discuss treatment
simplifications with their treating physician. A predictor of
simplification in this cohort was a higher nadir of lymphocyte
T CD4+, indicating that antiretroviral simplification is
primarily performed in safer conditions. In a study, the
median lymphocyte CD4+ at switch to TDF/FTC/RPV was
over 500/mmc and risk factors for discontinuations or
virological failure were lymphocyte CD4+ cell count below
200/mmc at the time of switch.38 Another predictor of
simplification is heterosexual contact as risk factor for HIV
transmission. Similarly to immigrants, heterosexual HIV-
infected subjects are more likely to be diagnosed late and
present advanced disease,39 probably because of a lower
perception of being at risk of HIV infection that may have led
to delayed testing: simplification strategies are justified in this
population that starts first-line cART with a more complex
regimen because of the wide immunological impairment or
owing to opportunistic infections.
Discontinuation due to intolerance is more likely to be
in patients with a concomitant use of statins indicating a pre-
existing alteration of lipid profile that can lead more
frequently to cART switch to improve metabolic profile and
reduce cardiovascular risk. The statins are more effective than
other classes of lipid-lowering drugs at reducing low-density
lipoproteins cholesterol; they reduce the risk of heart disease,
stroke, diabetes, and death.40 When considering treatment




Relative Hazards of Discontinuation
Due to Intolerance









(95% CI) P Global P
Adjusted Relative
Hazards (95% CI) P Global P
Time from HIV diagnosis
to date of starting
cART
Per year longer 1.02 (0.97 to 1.07) 0.449 0.98 (0.92 to 1.03) 0.421 0.98 (0.93 to 1.04) 0.496
eGFR (CKD_Epi
formula)
Per 60 mL/min per
1.73 m higher
0.56 (0.12 to 2.62) 0.462 0.82 (0.14 to 4.84) 0.823 0.63 (010 to 4.07) 0.623
Blood glucose




1.00 ,0.001 1.00 ,0.001 1.00 ,0.001
Zidovudine/lamivudine 0.62 (0.14 to 2.74) 0.527 2.26 (0.80 to 6.39) 0.125 3.72 (1.04 to 13.34) 0.044
Abacavir/lamivudine 0.88 (0.41 to 1.87) 0.734 015 (0.02 to 1.09) 0.060 0.55 (0.16 to 1.87) 0.340
Other NRTI pair 2.05 (0.28 to
15.04)
0.478 3.18 (0.79 to
12.82)
0.104 1.87 (0.11 to 32.21) 0.667
Third drug started
NNRTI (yes versus no) 3.14 (0.15 to
65.49)
0.461 5.01 (0.47 to
52.76)
0.180 8.46 (0.51 to 141.8) 0.138




0.765 3.12 (0.30 to
32.05)
0.338 14.26 (0.83 to 245.5) 0.067




0.861 1.42 (0.22 to 9.05) 0.710 1.69 (0.11 to 27.16) 0.710
Mental health disorders
(yes versus no)
0.23 (0.03 to 1.73) 0.154 2.50 (0.65 to 9.54) 0.181
*HDL level: .40 mg/dL for men and .50 mg/dL for women.
eGFR, estimated glomerular filtration rate; NRTI, nucleoside analog reverse transcriptase inhibitors; NNRTI, non-nucleoside analog reverse transcriptase inhibitors; r, ritonavir.
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switches to improve tolerability, it is critical to consider the
agent with less impact on lipid profile.
As previously reported,12,41 individuals starting a zido-
vudine/lamivudine-based regimens were more likely to
modify their treatment because of toxicity compared to those
treated with TDF/FTC-based regimens. Switch from zidovu-
dine was associated with significant improvements in hemo-
globin level and neutrophil counts parameters.42 Also, switch
from a thymidine analog to TDF leads to significant
improvement in limb fat mass, metabolic parameters, and
mitochondrial toxicity.43–46
The impressive number of patients (99%) who achieve
HIV-RNA below ,50 copies per milliliter gives the magni-
tude of the success of cART in the ICONA cohort and in
Italian population. In fact, despite the discontinuation of the
first-line cART, almost all patients resume therapy and are
able to obtain a virological success.
Some limitations should be recognized when interpret-
ing the results of our study: the heterogeneity of the collection
of the data on the single reason for discontinuation in cases of
concomitant reasons (although this bias has been partially
corrected by close central monitoring of all data), the potential
poor ascertainment of mental health disorders that might have
introduced bias because of residual confounding, the low
number of events of interest. Another limitation is that
patients’ mental health disorders and depression are recorded
in the ICONA database although likely to be underestimated,
and for this reason, they are not included in the analysis of
predictors of discontinuation. However, the strength of this
study is the large sample size and the ability to represent the
prescription trend including very recent years of enrollment.
In conclusion, the choice of different initial antiretro-
viral regimens in ICONA confirmed that there are differences
in prescription practices in different Italian sites, whereas in
second-line regimen simplification to STR appeared the
preferred choice. As observed in clinical studies, virological
success, measured with HIV-RNA below 50 copies per
milliliter, is well defined also in practice. A clear trend
toward tailored cART was highlighted. Further research
evaluating the impact of the introduction in clinical practice
of integrase inhibitors is needed.
REFERENCES
1. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir,
zidovudine, and lamivudine in adults with human immunodeficiency
virus infection and prior antiretroviral therapy. N Engl J Med. 1997;337:
734–739.
2. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two
nucleoside analogues plus indinavir in persons with human immunode-
ficiency virus infection and CD4 cell counts of 200 per cubic millimeter
or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med.
1997;337:725–733.
3. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and
mortality among patients with advanced human immunodeficiency virus
infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338:
853–860.
4. Ray M, Logan R, Sterne JA, et al. The effect of combined antiretroviral
therapy on the overall mortality of HIV-infected individuals. AIDS. 2010;
24:123–137.
5. Li TS, Tubiana R, Katlama C, et al. Long-lasting recovery in CD4 T-cell
function and viral-load reduction after highly active antiretroviral therapy
in advanced HIV-1 disease. Lancet. 1998;351:1682–1686.
6. Detels R, Tarwater P, Phair JP, et al. Effectiveness of potent antiretroviral
therapies on the incidence of opportunistic infections before and after
AIDS diagnosis. AIDS. 2001;15:347–355.
7. Vo TT, Ledergerber B, Keiser O, et al; for the Swiss HIV Cohort Study.
Durability and outcome of initial antiretroviral treatments received during
2000–2005 by patients in the Swiss HIV Cohort Study. J Infect Dis.
2008;197:1685–1694.
8. D’Arminio Monforte A, Cozzi Lepri A, Rezza G, et al. Insights into the
reasons for discontinuation of the first highly active antiretroviral therapy
(HAART) regimen in a cohort of antiretroviral naıve patients. AIDS.
2000;14:499–507.
9. Yuan Y, L’Italien G, Mukherjee J, et al. Determinants of discontinuation
of initial highly active antiretroviral therapy regimens in a US HIV-
infected patient cohort. HIV Med. 2006;7:156–162.
10. Hart E, Curtis H, Wilkins E, et al. National review of first treatment
change after starting highly active antiretroviral therapy in antiretroviral-
naıve patients. HIV Med. 2007;8:186–191.
11. Cicconi P, Cozzi-Lepri A, Castagna A, et al. Insights into reasons for
discontinuation according to year of starting first regimen of highly active
antiretroviral therapy in a cohort of antiretroviral-naıve patients. HIV
Med. 2010;11:104–113.
12. Elzi L, Marzolini C, Furrer H, et al. Treatment modification in human
immunodeficiency virus-infected individuals starting combination anti-
retroviral therapy between 2005 and 2008. Arch Intern Med. 2010;170:
57–65.
13. Hughes AJ, Mattson CL, Scheer S, et al. Discontinuation of antiretroviral
therapy among adults receiving HIV care in the United States. J Acquir
Immune Defic Syndr. 2014;66:80–89.
14. Grint D, Peters L, Rockstroh JK, et al. Increased incidence of
antiretroviral drug discontinuation among patients with viremic hepatitis
C virus coinfection and high hyaluronic acid, a marker of liver fibrosis.
AIDS. 2014;28:577–587.
15. Slama L, Li X, Brown T, et al. Increases in duration of first highly active
antiretroviral therapy over time (1996–2009) and associated factors in the
multicenter AIDS cohort study. J Acquir Immune Defic Syndr. 2014;65:57–64.
16. Gonzalez-Serna A, Chan K, Yip B, et al. Temporal trends in the
discontinuation of first-line antiretroviral therapy. J Antimicrob Chemo-
ther. 2014;69:2202–2209.
17. Samji H, Taha TE, Moore D, et al. Predictors of unstructured
antiretroviral treatment interruption and resumption among HIV-
positive individuals in Canada. HIV Med. 2015;16:76–87.
18. Guidelines for the use of Antiretroviral Agents in HIV-1-Infected Adults
and Adolescents. Available at: http://aidsinfo.nih.gov/guidelines. Ac-
cessed May 1, 2015.
19. Raffi F, Pozniak AL, Wainberg MA. Has the time come to abandon
efavirenz for first-line antiretroviral therapy? J Antimicrob Chemother.
2014;69:1742–1747.
20. Ahdieh-Grant L, Tarwater PM, Schneider MF, et al. Factors and temporal
trends associated with highly active antiretroviral therapy discontinuation
in the Women’s Interagency HIV Study. J Acquir Immune Defic Syndr.
2005;38:500–503.
21. Mocroft A, Youle M, Moore A, et al. Reasons for modification and
discontinuation of antiretrovirals: results from a single treatment centre.
AIDS. 2001;15:185–194.
22. Prosperi MCF, Fabbiani M, Fanti I, et al. Predictors of first-line
antiretroviral therapy discontinuation due to drug-related adverse events
in HIV-infected patients: a retrospective cohort study. BMC Infect Dis.
2012;12:296.
23. Linee Guida Ita Linee Guida Italiane sull’utilizzo dei farmaci
antiretrovirale e sulla gestione diagnostico-clinica delle persone con
infezione da HIV-1. Available at: http://www.salute.gov.it/imgs/C_17_
pubblicazioni_2261_allegato.pdf. Accessed May 1, 2015.
24. Willig JH, Abroms S, Westfall AO, et al. Increased regimen durability in
the era of once daily fixed-dose combination antiretroviral therapy. AIDS.
2008;22:1951–1960.
25. Astuti N, Maggiolo F. Single-tablet regimens in HIV therapy. Infect Dis
Ther. 2014;3:1–17.
26. Aldir I, Horta A, Serrado A. Single tablet regimens in HIV: does it really
make a difference? Curr Med Res Opin. 2014;30:89–97.
27. Guaraldi G, Prakash M, Moecklinghoff C, et al. Morbidity in older HIV-
infected patients: impact of long-term antiretroviral use. AIDS Rev. 2014;
16:75–89.
Di Biagio et al J Acquir Immune Defic Syndr  Volume 71, Number 3, March 1, 2016
270 | www.jaids.com Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.
Copyright © 201 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.5
28. Llibre JM, Cardona G, Santos JR, et al. Antiretroviral treatment switch
strategies for lowering the costs of antiretroviral therapy in subjects with
suppressed HIV-1 viremia in Spain. Clinicoecon Outcomes Res. 2013;5:
215–221.
29. Wainberg MA. Combination therapies, effectiveness, and adherence in
patients with HIV infection: clinical utility of a single tablet of
emtricitabine, rilpivirine, and tenofovir. HIV AIDS (Auckl). 2013;5:
41–49.
30. Palella FJ, Fisher M, Tebas P, et al. Simplification to rilpivirine/em-
tricitabine/tenofovir disoproxil fumarate from ritonavir-boosted protease
inhibitor antiretroviral therapy in a randomized trial of HIV-RNA-
suppressed patients. AIDS. 2014;28:335–344.
31. Gantner P, Reinhart S, Partisani M, et al. Switching to emtricitabine,
tenofovir and rilpivirine as single tablet regimen in virologically
suppressd HIV-1 infected patients: a cohort study. HIV Med. 2015;16:
132–136.
32. Mills AM, Cohen C, Dejesus E, et al. Efficacy and safety 48 weeks after
switching from efavirenz to rilpivirine using emtricitabine/tenofovir
disoproxil fumarate-based single-tablet regimens. HIV Clin Trials.
2013;14:216–223.
33. Bernardini C, Maggiolo F. Triple combination rilpivirine, emtricitabine,
and tenofovir (Complera/Eviplera) in the treatment of HIV. Patient
Prefer Adherence. 2013;7:531–542.
34. Sulis G, El Hamad I, Fabiani M, et al. Clinical and epidemiological
features of HIV/AIDS infection among migrants at first access to
healthcare services as compared to Italian patients in Italy: a retrospective
multicentre study, 2000–2010. Infection. 2014;42:859–863.
35. Girardi E, Sabin CA, d’Arminio Monforte A. Late diagnosis of HIV
infection: epidemiological features, consequences and strategies to
encourage earlier testing. J Acquir Immune Defic Syndr. 2007;45
(suppl 1):S3–S8.
36. Thierfelder C, Weber R, Elzi L, et al. Participation, characteristics and
retention rates of HIV-positive immigrants in the Swiss HIV Cohort
Study. HIV Med. 2012;13:118–126.
37. Oh DL, Sarafian F, Silvestre A, et al. Evaluation of adherence and factors
affecting adherence to combination antiretroviral therapy among white,
hispanic and black men in the MACS Cohort. J Acquir Immune Defic
Syndr. 2009;52:290–293.
38. Pinnetti C, Di Giambenedetto S, Maggiolo F, et al. Simplification to co-
formulated rilpivirine/emtricitabine/tenofovir in virologically suppressed
patients: data from a multicenter cohort. J Int AIDS Soc. 2014;17(4
suppl 3):19812.
39. Borghi V, Girardi E, Bellelli S, et al. Late presenters in an HIV
surveillance system in Italy during the period 1992-2006. J Acquir
Immune Defic Syndr. 2008;49:282–286.
40. Funderburg NT, Jiang Y, Debanne SM, et al. Rosuvastatin reduces
vascular inflammation and T-cell and monocyte activation in HIV-
infected subjects on antiretroviral therapy. J Acquir Immune Defic Syndr.
2015;68:396–404.
41. Smit M, Smit C, Geerlings S, et al. Athena Observational Cohort newer
regimens are associated with improved tolerability. Changes in first-line
cART regimens and short-term clinical outcome between 1996 and 2010
in The Netherlands. PLoS One. 2013;30:e76071.
42. Lafaurie M, Collin F, Bentata M, et al. Switch from zidovudine- to non-
zidovudine-containing regimens is associated with modes haematological
improvement and no obvius clinical benefit: a substudy of the ANRS 099
Alize trial. J Antimicrob Chemother. 2008;62:1122–1129.
43. Curran A, Ribera E. From old to new nucleoside reverse transcriptase
inhibitors: change in body fat composition, metabolic parameters and
mithocondrial toxicity after the switch from thymidine analogs to
tenofovir or abacavir. Expert Opin Drug Saf. 2011;10:389–406.
44. Moyle GJ, Sabin CA, Carttledge J, et al. A randomized comparative trial
of tenofovir DF or abacavir as replacement for a thymidine analogue in
persons with lipoathrophy. J Acquir Immune Defic Syndr. 2006;20:2043–
2050.
45. Reust CE. Common adverse effects of antiretroviral therapy for HIV
disease. Am Fam Physician. 2011;12:1443–1451.
46. Pozniak A, Gallant JE, DeJesus E, et al. Tenofovir disoproxil fumarate,
emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine
and efavirenz in antiretroviral-naive patients: virologic, immunologic,
and morphologic changes—a 96-week analysis. J Acquir Immune Defic
Syndr. 2006;43:535–540.
APPENDIX 1. Icona Foundation Study Group
Board of Directors
M Moroni (Chair), M Andreoni, G Angarano, A Antinori, A
d’Arminio Monforte, F Castelli, R Cauda, G Di Perri, M Galli, R Iardino,
G Ippolito, A Lazzarin, CF Perno, F von Schloesser, P Viale.
Scientific Secretary
A d’Arminio Monforte, A Antinori, A Castagna, F Ceccherini-
Silberstein, A Cozzi-Lepri, E Girardi, S Lo Caputo, C Mussini, M Puoti.
Steering Committee
M Andreoni, A Ammassari, A Antinori, C Balotta, A Bandera, P
Bonfanti, S Bonora, M Borderi, A Calcagno, L Calza, MR Capobianchi, A
Castagna, F Ceccherini-Silberstein, A Cingolani, P Cinque, A Cozzi-Lepri, A
d’Arminio Monforte, A De Luca, A Di Biagio, E Girardi, N Gianotti, A Gori,
G Guaraldi, G Lapadula, M Lichtner, S Lo Caputo, G Madeddu, F Maggiolo,
G Marchetti, S Marcotullio, L Monno, C Mussini, M Puoti, E Quiros Roldan,
R Rossotti, S Rusconi, M Santoro, A Saracino, M Zaccarelli.
Statistical and Monitoring Team
A Cozzi-Lepri, I Fanti, L Galli, P Lorenzini, A Rodano, M Shanyinde,
A Tavelli.
Participating Physicians and Centers
Italy: A Giacometti, A Costantini, S Mazzoccato (Ancona); G
Angarano, L Monno, C Santoro (Bari); F Maggiolo, C Suardi (Bergamo);
P Viale, E Vanino, G Verucchi (Bologna); F Castelli, E Quiros Roldan, C
Minardi (Brescia); T Quirino, C Abeli (Busto Arsizio); PE Manconi, P Piano
(Cagliari); J Vecchiet, K Falasca (Chieti); L Sighinolfi, D Segala (Ferrara); F
Mazzotta, S Lo Caputo (Firenze); G Cassola, C Viscoli, A Alessandrini, R
Piscopo, G Mazzarello (Genova); C Mastroianni, V Belvisi (Latina); P
Bonfanti, I Caramma (Lecco); A Chiodera, AP Castelli (Macerata); M Galli,
A Lazzarin, G Rizzardini, M Puoti, A d’Arminio Monforte, AL Ridolfo, R
Piolini, A Castagna, S Salpietro, L Carenzi, MC Moioli, C Tincati, G.
Marchetti (Milano); C Mussini, C Puzzolante (Modena); A Gori, G. Lapadula
(Monza); N Abrescia, A Chirianni, G Borgia, MG Guida, M Gargiulo, I
Gentile, R Orlando (Napoli); F Baldelli, D Francisci (Perugia); G Parruti, T
Ursini (Pescara); G Magnani, MA Ursitti (Reggio Emilia); R Cauda, M.
Andreoni, A Antinori, V Vullo, A. Cingolani, A d’Avino, L Gallo, E Nicastri,
R Acinapura, M Capozzi, R Libertone, G Tebano, M Zaccarelli (Roma); F
Viviani, L Sasset (Rovigo); MS Mura, G Madeddu (Sassari); A De Luca, B
Rossetti (Siena); P Caramello, G Di Perri, GC Orofino, S Bonora, M Sciandra
(Torino); M Bassetti, A Londero (Udine); G Pellizzer, V Manfrin (Vicenza).
J Acquir Immune Defic Syndr  Volume 71, Number 3, March 1, 2016 Discontinuation of First-Line Regimen in the Antiretroviral Era
Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved. www.jaids.com | 271
Copyright © 201 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.5
